Have a prescription? Buy Blincyto from Canada and experience the following benefits:

  • Cost Savings: Significantly Lower Prices compared to the US.
  • Bulk Discounts: Save More on Quantity (Limit: 90-day supply).
  • Express Ships from Canada: Fast & Efficient Shipping Directly to your Doorstep.
  • Secure Ordering: Buy Blincyto Online or by Phone at 1-888-513-2294
  • SAVE 10% on first order with coupon code: FIRST10
Buy BLINCYTO from Canada
Select product strength & quantity:

Prescription Required.

Product of Canada.

Shipped from Canada.

Prescription Required.Product of Canada.Shipped from Canada.

BLINCYTO® (blinatumomab) stands as a pivotal development in the realm of oncology, specifically in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow. This prescription medication has emerged as a beacon of hope for both adults and children grappling with this challenging condition. Its approval and subsequent use have marked a significant milestone in the journey towards more effective leukemia treatments.

BLINCYTO® is particularly noteworthy for its role in treating patients who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of a small number of cancer cells that remain in the body after treatment, which can be a precursor to relapse. BLINCYTO®’s ability to target these cells is crucial in reducing the risk of leukemia returning, thus offering a chance for a more sustained remission.

Moreover, BLINCYTO® is a key therapeutic option for patients with relapsed or refractory ALL. In cases where the leukemia does not respond to standard treatments or returns after initial therapy, BLINCYTO® provides a new avenue for treatment, often leading to positive outcomes where other therapies have failed. This is particularly significant given the aggressive nature of ALL and the limited options available for relapsed or refractory cases.

The introduction of BLINCYTO® represents a significant advancement in leukemia therapy. Its unique mechanism of action, which involves recruiting the body’s own immune cells to fight cancer, has opened new doors in the understanding and treatment of ALL. For patients, particularly those with specific risk factors for relapse, BLINCYTO® offers not just a treatment option, but a renewed sense of hope and a possibility for a better prognosis. This medication exemplifies the progress being made in targeted cancer therapies, highlighting the ongoing commitment to developing more effective and personalized treatment options for cancer patients.


BLINCYTO® is the trade name for blinatumomab, a groundbreaking cancer treatment classified as a bispecific CD19-directed CD3 T-cell engager. This innovative medication is a form of targeted immunotherapy, designed to harness the body’s immune system in the fight against cancer. Blinatumomab’s mechanism of action is unique and highly specific: it acts as a connector between cancerous B-cells and the body’s T-cells. B-cells, in the context of acute lymphoblastic leukemia (ALL), are the malignant cells, while T-cells are crucial components of the immune system’s defense mechanism.

By linking these two types of cells, BLINCYTO® effectively directs the body’s own immune response against the cancerous cells. This action triggers the T-cells to recognize, engage, and ultimately destroy the B-cells harboring the leukemia. This approach is particularly innovative because it bypasses the need for the body’s natural immune recognition processes, which can be evaded by cancer cells.

As a monoclonal antibody, BLINCYTO® represents a new era in cancer treatment, especially in targeting specific leukemia cells in ALL. Its ability to directly engage the immune system in targeting cancer cells makes it a powerful tool in the treatment of this aggressive form of leukemia. The precision of this therapy lies in its dual targeting mechanism, which is designed to minimize harm to healthy cells while maximizing the destruction of cancerous cells.

Medical Uses

Acute lymphoblastic leukemia (ALL) is a rapidly progressing cancer that primarily affects the white blood cells (lymphocytes) in the blood and bone marrow. It is characterized by the overproduction of immature lymphocytes, known as lymphoblasts. These abnormal cells crowd out normal blood cells, leading to various health complications.

BLINCYTO® is specifically used in the treatment of B-cell precursor ALL, which is a common subtype of this leukemia. Its role is particularly vital in two scenarios: first, in patients who have achieved remission but still show signs of minimal residual disease (MRD), and second, in patients with relapsed or refractory ALL. MRD refers to the presence of a small number of cancer cells that remain after treatment and can lead to a relapse. BLINCYTO®’s ability to target these cells reduces the likelihood of the leukemia returning, offering a chance for a more durable remission.

In cases of relapsed or refractory ALL, where the disease either returns after treatment or does not respond to standard therapies, BLINCYTO® provides a critical treatment option. Its effectiveness in these challenging situations can significantly improve the prognosis for patients, offering a potential path to long-term remission. The use of BLINCYTO® in these contexts underscores its importance as a therapeutic advancement, providing hope and a viable treatment option for patients facing limited alternatives.


BLINCYTO® (blinatumomab) represents a significant breakthrough in cancer immunotherapy, functioning as a bispecific CD19-directed CD3 T-cell engager. This innovative mechanism of action is central to its effectiveness in treating B-cell precursor acute lymphoblastic leukemia (ALL). BLINCYTO® uniquely binds to two different proteins: CD19, an antigen found on the surface of B-cells, including the malignant B-cells characteristic of ALL, and CD3, located on T-cells, which are key components of the body’s immune response.

The dual binding action of BLINCYTO® brings these two types of cells into close proximity. This interaction activates the T-cells, turning them into potent attackers against the B-cells. By directly engaging the body’s immune system, BLINCYTO® effectively targets and destroys the cancerous B-cells. This targeted approach is particularly beneficial in treating ALL, as it focuses the immune system’s attack specifically on the cancer cells, sparing healthy cells and reducing collateral damage.

The effectiveness of BLINCYTO® is most pronounced in cases where minimal residual disease (MRD) is present and in relapsed or refractory ALL. MRD refers to the small number of cancer cells that can remain after treatment and potentially lead to a relapse. BLINCYTO®’s ability to target these cells reduces the risk of the leukemia returning, offering a chance for a more durable remission. In relapsed or refractory cases, where the disease either returns after treatment or does not respond to standard therapies, BLINCYTO® provides a critical treatment option, often leading to positive outcomes where other therapies have failed.

Dosage and Administration

BLINCYTO® is administered through a continuous intravenous infusion over a period of 28 days, followed by a two-week treatment-free interval. This cycle can be repeated based on the patient’s response to the treatment and clinical judgment. The administration of BLINCYTO® requires meticulous preparation and handling. It is supplied as a single-use vial containing lyophilized powder, which must be reconstituted and diluted prior to administration.

Given the potential for cytokine release syndrome (CRS) and neurological toxicities, the initial dose of BLINCYTO® is administered at a lower level and then increased after the first week of treatment. This cautious approach is necessary to monitor and manage potential adverse reactions effectively. Healthcare providers are required to closely monitor patients during the treatment, particularly during the initial 48 hours of the first and second cycles, to ensure patient safety and the effectiveness of the therapy. This vigilant monitoring is crucial in managing the risks associated with BLINCYTO® and in achieving the best possible outcomes for patients undergoing treatment.

Side Effects of BLINCYTO®

The administration of BLINCYTO® (blinatumomab) can lead to a range of side effects, varying in severity and impact on patients. Understanding these side effects is crucial for both healthcare providers and patients to manage and mitigate potential risks effectively.

Common Side Effects

The most frequently observed side effects of BLINCYTO® include:

  • Fever: A common reaction, often manageable with antipyretics or other supportive care.
  • Infections: Patients may be more susceptible to infections, including upper respiratory and urinary tract infections.
  • Headache: This can range from mild to severe and may require symptomatic treatment.
  • Peripheral Edema: Swelling of limbs or extremities, which can be managed with appropriate interventions.
  • Nausea: Often controlled with dietary adjustments or antiemetic medications.
  • Hypokalemia: Low potassium levels in the blood, which may necessitate dietary adjustments or supplements.
  • Constipation: Can be managed with dietary fiber, hydration, and, if necessary, laxatives.

These side effects are generally manageable with appropriate medical intervention and do not usually necessitate discontinuation of the therapy.

Serious Side Effects

BLINCYTO® can also cause serious, potentially life-threatening side effects, including:

  • Cytokine Release Syndrome (CRS): Symptoms include fever, chills, difficulty breathing, and fatigue. CRS requires immediate medical attention and may be managed with corticosteroids or other treatments.
  • Neurological Toxicities: These can range from tremors, confusion, and aphasia to more severe conditions like seizures. Close monitoring and intervention are crucial.
  • Infections: Severe infections, including sepsis, may occur and require aggressive antibiotic treatment.
  • Tumor Lysis Syndrome: This occurs when cancer cells break down rapidly, releasing their contents into the bloodstream, and requires immediate treatment.

Long-term Risks and Considerations

Long-term use of BLINCYTO® necessitates careful monitoring for these serious side effects. Patients should be thoroughly informed about the symptoms of CRS, neurological events, and other serious side effects. They should be instructed to seek immediate medical attention if they experience any concerning symptoms. Regular follow-up appointments and monitoring tests are essential to detect and address these side effects promptly. This vigilant approach ensures that patients receive the full therapeutic benefits of BLINCYTO® while minimizing the risks associated with its use.

Warnings and Precautions for BLINCYTO®

The use of BLINCYTO® (blinatumomab) requires careful consideration due to its potential to cause serious and sometimes life-threatening side effects. Understanding these risks is crucial for both healthcare providers and patients to ensure safe and effective treatment.

Cytokine Release Syndrome (CRS) and Infusion Reactions

  • CRS: One of the most significant risks associated with BLINCYTO® is Cytokine Release Syndrome. CRS can manifest with symptoms like fever, fatigue, dizziness, headache, low blood pressure, nausea, vomiting, chills, facial swelling, breathing difficulties, and skin rashes. These symptoms can range from mild to severe and require immediate medical attention.
  • Infusion Reactions: BLINCYTO® can also cause infusion reactions, which may occur during or within 24 hours of the infusion. Patients should be monitored closely during and after the infusion for any signs of an adverse reaction.

Neurological Toxicities

  • Range of Symptoms: BLINCYTO® can cause various neurological problems, which can be severe and impact the quality of life. Symptoms to watch for include seizures, speech difficulties, loss of consciousness, insomnia, confusion, disorientation, loss of balance, headaches, difficulty with facial movements, and problems with hearing, vision, or swallowing.
  • Monitoring and Management: Due to the risk of neurological toxicities, patients receiving BLINCYTO® should be closely monitored. If severe neurological symptoms occur, treatment may need to be interrupted or discontinued. Patients and caregivers should be informed about these risks and advised to report any neurological symptoms immediately.

Management of Severe Side Effects

  • Intervention Strategies: In cases of severe CRS, infusion reactions, or neurological toxicities, healthcare providers may need to temporarily or permanently discontinue BLINCYTO®. Treatment for these side effects may include hospitalization, administration of corticosteroids, or other supportive care measures.
  • Patient Education: Patients receiving BLINCYTO® should be thoroughly educated about the potential side effects and the importance of immediate reporting of any adverse symptoms. They should also be informed about the procedures for managing these side effects, including the possibility of treatment interruption or discontinuation.

In summary, while BLINCYTO® offers a significant therapeutic benefit in treating B-cell precursor acute lymphoblastic leukemia, its use is accompanied by serious risks that require vigilant monitoring and prompt management. Healthcare providers play a crucial role in educating patients, monitoring for side effects, and implementing appropriate interventions to ensure patient safety during BLINCYTO® treatment.

Interactions with Other Medications

The treatment with BLINCYTO® (blinatumomab) necessitates a comprehensive understanding of its potential interactions with other medications. These interactions can significantly impact the effectiveness of the treatment and the patient’s overall safety.

Comprehensive Medication Disclosure

  • Full Medication List: Patients are advised to provide their healthcare providers with a complete list of all medications they are currently taking. This includes not only prescription drugs but also over-the-counter medicines, vitamins, and herbal supplements. The reason for this thorough disclosure is that BLINCYTO® can interact with other medications, potentially leading to increased side effects or reduced effectiveness of the treatment.
  • Importance of Accuracy: Accurate and complete information about all medications is crucial for healthcare providers to make informed decisions about the use of BLINCYTO® and to manage potential drug interactions effectively.

Avoidance of Live Vaccines

  • Vaccination Guidelines: Patients planning to start treatment with BLINCYTO® should avoid receiving “live vaccines” for at least 2 weeks before the initiation of the therapy. This precaution should also be maintained during the treatment period and until the immune system has fully recovered after the last cycle of BLINCYTO®.
  • Risk of Infection: The reason behind this precaution is that live vaccines can pose a risk of infection, especially in patients whose immune systems are compromised or weakened by treatments like BLINCYTO®.

Contraindicated Medications

  • Medications to Avoid: Certain medications should not be used in combination with BLINCYTO®. These include drugs that may exacerbate the side effects of BLINCYTO® or interfere with its mechanism of action. For instance, medications that suppress the immune system or those that can increase the risk of infections or bleeding may pose additional risks when used alongside BLINCYTO®.
  • Healthcare Provider Consultation: It is essential for patients to consult with their healthcare providers before starting any new medications, including over-the-counter drugs and supplements, while on BLINCYTO® treatment. This consultation helps to ensure that any new medication does not adversely interact with BLINCYTO®.

In summary, managing interactions with other medications is a critical aspect of BLINCYTO® treatment. Patients must be proactive in disclosing all medications they are taking and adhere to guidelines regarding vaccinations and contraindicated drugs. Healthcare providers play a key role in monitoring these interactions to ensure the safe and effective use of BLINCYTO®.

Use in Specific Populations

The administration of BLINCYTO® (blinatumomab) requires careful consideration of the patient’s overall health and specific medical history. This is particularly important due to the medication’s potent mechanism of action and the potential for serious side effects.

Comprehensive Medical History Review

  • Pre-existing Conditions: Patients considering BLINCYTO® treatment should provide their healthcare providers with a detailed medical history. This includes any history of neurological problems, such as seizures or cognitive disorders, which could be exacerbated by BLINCYTO®. A history of infections is also crucial, as BLINCYTO® can weaken the immune system, increasing the risk of new or recurrent infections.
  • Previous Treatments: Information about prior treatments, especially those involving the immune system or the brain, such as radiation therapy or chemotherapy, is important. These treatments can impact the patient’s response to BLINCYTO® and the likelihood of experiencing certain side effects.

Considerations for Pregnancy and Breastfeeding

  • Pregnancy: BLINCYTO® is not recommended for use during pregnancy due to the potential risk to the developing fetus. Women of childbearing age should be advised to use effective contraception during treatment and for at least 48 hours following the last dose of BLINCYTO®. If a patient becomes pregnant while on BLINCYTO®, the treatment should be reassessed, and the patient should be counseled about the potential risks to the fetus.
  • Breastfeeding: Similarly, breastfeeding is not recommended during BLINCYTO® treatment and for 48 hours after the final dose. The effects of BLINCYTO® on breastfed infants are unknown, but the potential for serious adverse reactions in nursing infants cannot be ruled out.

Special Precautions

  • Informed Decision-Making: Patients should be fully informed about the potential risks and benefits of BLINCYTO® treatment, especially in the context of their individual health circumstances.
  • Regular Monitoring: For patients who proceed with BLINCYTO® treatment, regular monitoring and follow-up are essential to manage any emerging side effects or complications effectively.

The use of BLINCYTO® in specific populations requires a thorough evaluation of the patient’s medical history, current health status, and future plans regarding pregnancy and breastfeeding. This comprehensive approach ensures that the treatment is not only effective but also safe for the patient’s specific circumstances.

Storage and Handling of BLINCYTO®

Proper storage and handling of BLINCYTO® (blinatumomab) are critical to preserving its effectiveness and ensuring the safety of the treatment. Both healthcare professionals and patients (or caregivers) play a vital role in maintaining the integrity of this medication.

Storage Requirements

  • Temperature and Conditions: BLINCYTO® must be stored at the temperature specified in the prescription information, typically at controlled room temperature. It’s crucial to avoid exposing the medication to extreme temperatures, either too hot or too cold, as this can affect its stability and effectiveness.
  • Environment: The medication should be kept in its original packaging to protect it from light and moisture. It should not be stored in places with high humidity, such as bathrooms, or in direct sunlight.

Handling Procedures

  • Preparation for Infusion: The preparation of BLINCYTO® for infusion should be conducted following strict aseptic techniques. This process involves reconstituting and diluting the medication as per the guidelines provided. Only trained healthcare professionals should handle and prepare the medication to ensure it’s done correctly.
  • Disposal of Unused Medication: Any unused BLINCYTO® should be disposed of in a safe and appropriate manner. Unused or expired medication should not be disposed of in household trash or flushed down the toilet. Instead, follow specific guidelines for hazardous waste disposal, or return the medication to a pharmacy or a medical facility that accepts medication returns.

Education for Patients and Caregivers

  • Importance of Proper Handling: Patients and caregivers should be thoroughly educated on the importance of proper storage and handling of BLINCYTO®. This includes instructions on where to store the medication, how to check for expiration dates, and whom to contact for disposal.
  • Safety Measures: Clear instructions should be provided on safety measures to be taken during handling, especially if the medication needs to be stored at home. This includes wearing gloves if direct contact with the medication is necessary and ensuring that children and pets cannot access the medication.

In summary, the effective storage and handling of BLINCYTO® are essential components of the treatment process. Adhering to the recommended guidelines ensures the medication’s efficacy and safety, contributing to the successful management of the patient’s condition.

Frequently Asked Questions

BLINCYTO® is used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. It’s particularly effective for patients in remission with minimal residual disease (MRD) and those with relapsed or refractory ALL.

BLINCYTO® functions as a bispecific CD19-directed CD3 T-cell engager. It connects B-cells, which are cancer cells in ALL, to T-cells, activating the immune system to attack and destroy these cancer cells.

Individuals allergic to blinatumomab or any of BLINCYTO®’s ingredients should avoid it. Patients with a history of neurological problems, infections, infusion reactions, radiation to the brain, or certain chemotherapy treatments should consult their doctor before using BLINCYTO®.

Common side effects include fever, infections, headache, peripheral edema, nausea, hypokalemia, and constipation. These are generally manageable with medical intervention.

Yes, serious side effects can include Cytokine Release Syndrome (CRS), neurological toxicities, severe infections, and tumor lysis syndrome. These can be life-threatening and require immediate medical attention.

BLINCYTO® is not recommended during pregnancy. Women who are pregnant or planning to become pregnant should discuss the risks with their healthcare provider.

Breastfeeding is not recommended during treatment with BLINCYTO® and for 48 hours after the last dose, as it’s unknown if it passes into breast milk.

BLINCYTO® is given as a continuous intravenous infusion over 28 days, followed by a 2-week treatment-free interval. This cycle may be repeated based on the patient’s response.

Avoid driving, operating heavy machinery, or performing dangerous activities, as BLINCYTO® can cause neurological symptoms like dizziness and confusion.

Yes, BLINCYTO® may cause life-threatening infections. Patients should report any signs or symptoms of an infection to their healthcare provider immediately.

TLS is caused by the rapid breakdown of cancer cells and can be life-threatening. Symptoms include nausea, vomiting, confusion, irregular heartbeat, and cloudy urine.

Contact your healthcare provider immediately if you experience unusual or severe side effects, including signs of CRS, neurological problems, or infections.

Store BLINCYTO® at the recommended temperature and conditions as specified in the prescription information. Proper storage is essential for maintaining its effectiveness.

Yes, BLINCYTO® is approved for use in children with B-cell precursor ALL. However, it should be used under strict medical supervision.

Inform your healthcare provider about all your medical conditions and medications. Avoid live vaccines before and during treatment and follow all safety guidelines for handling and administration.

Avoid live vaccines within 2 weeks before starting BLINCYTO®, during treatment, and until your immune system recovers after the last cycle.

Infusion reactions may include symptoms like low blood pressure, high blood pressure, face swelling, and difficulty breathing. These require immediate medical attention.

Financial assistance programs may be available for eligible patients. Consult the BLINCYTO® website or your healthcare provider for more information.

BLINCYTO® can cause low white blood cell counts (neutropenia), increasing the risk of infection. Regular blood tests are necessary to monitor this.

BLINCYTO® may cause abnormal liver blood tests. Your healthcare provider will monitor your liver function before and during treatment with BLINCYTO®.